Response to Comment on: “Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study”
- 3 February 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Clinical Drug Investigation
- Vol. 40 (3), 289-290
- https://doi.org/10.1007/s40261-020-00890-x
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Comment On: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study"Clinical Drug Investigation, 2020
- Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort StudyClinical Drug Investigation, 2019
- Anticoagulating obese patients in the modern eraBritish Journal of Haematology, 2011
- Effect of Obesity on the Pharmacokinetics of Drugs in HumansClinical Pharmacokinetics, 2010
- Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical SettingsAnnals of Pharmacotherapy, 2009
- Development of a dosing strategy for enoxaparin in obese patientsBritish Journal of Clinical Pharmacology, 2003